Insider Selling: Palvella Therapeutics (NASDAQ:PVLA) Director Sells $935,202.64 in Stock

Palvella Therapeutics, Inc. (NASDAQ:PVLA) Director George Jenkins sold 7,174 shares of the company’s stock in a transaction on Tuesday, October 13th. The shares were sold at an average price of $130.36, for a total value of $935,202.64. Following the transaction, the director directly owned 139,790 shares in the company, valued at approximately $18,223,024.40. The trade was a 4.88% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Palvella Therapeutics Stock Down 5.5%

Palvella Therapeutics stock opened at $120.30 on Friday. Palvella Therapeutics, Inc. has a one year low of $68.96 and a one year high of $161.38. The business’s fifty day moving average is $145.44 and its 200 day moving average is $134.33.

Palvella Therapeutics (NASDAQ:PVLA) last issued its earnings results on Tuesday, August 4th. The company reported ($1.52) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.17) by ($0.35). As a group, research analysts anticipate that Palvella Therapeutics, Inc. will post -6.40 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the company. BlackRock Inc. purchased a new position in Palvella Therapeutics in the second quarter worth about $140,343,000. Summit Partners Public Asset Management LLC grew its stake in shares of Palvella Therapeutics by 1,016.0% during the 4th quarter. Summit Partners Public Asset Management LLC now owns 389,420 shares of the company’s stock valued at $40,761,000 after purchasing an additional 354,525 shares during the period. First Light Asset Management LLC grew its stake in shares of Palvella Therapeutics by 38.3% during the 1st quarter. First Light Asset Management LLC now owns 980,758 shares of the company’s stock valued at $122,251,000 after purchasing an additional 271,617 shares during the period. Primecap Management Co. CA purchased a new stake in shares of Palvella Therapeutics during the 2nd quarter valued at about $39,150,000. Finally, Jennison Associates LLC increased its position in shares of Palvella Therapeutics by 65.3% during the 1st quarter. Jennison Associates LLC now owns 640,611 shares of the company’s stock valued at $79,852,000 after purchasing an additional 253,128 shares during the last quarter. Institutional investors own 40.11% of the company’s stock.

Analyst Ratings Changes

Several research analysts have recently weighed in on PVLA shares. HC Wainwright decreased their price objective on shares of Palvella Therapeutics from $270.00 to $246.00 and set a “buy” rating for the company in a report on Monday, October 12th. Raymond James Financial set a $226.00 price objective on shares of Palvella Therapeutics in a research report on Friday. Truist Financial set a $207.00 target price on shares of Palvella Therapeutics in a report on Wednesday, August 5th. Canaccord Genuity Group set a $232.00 target price on shares of Palvella Therapeutics in a research report on Wednesday, August 5th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Palvella Therapeutics in a research note on Friday, September 25th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $209.79.

Key Headlines Impacting Palvella Therapeutics

Here are the key news stories impacting Palvella Therapeutics this week:

• Positive Sentiment: William Blair initiated coverage with an Outperform rating. The new bullish analyst coverage adds credibility to Palvella’s long-term opportunity and may support investor interest in its rare-disease pipeline. William Blair initiates coverage
• Positive Sentiment: New pediatric analyses for QTORIN rapamycin showed improvements in disease severity and lesion characteristics. Results from the Phase 3 SELVA and Phase 2 TOIVA studies highlighted improvements in children with microcystic lymphatic malformations and cutaneous venous malformations. QTORIN could potentially become the first FDA-approved treatment for these conditions, although the therapy remains investigational. Palvella pediatric QTORIN analyses
• Neutral Sentiment: HC Wainwright retained its Buy rating and $246 price target. Its 2027 quarterly estimates imply continued losses—$2.40, $2.59, $4.16 and $4.36 per share from the first through fourth quarters—underscoring that profitability remains distant despite the optimistic valuation target. HC Wainwright PVLA estimates
• Negative Sentiment: Director George Jenkins sold an additional 13,152 shares for approximately $1.76 million. This followed a sale of 7,174 shares worth about $935,000, with both transactions conducted under a pre-arranged Rule 10b5-1 plan. Repeated insider selling can weigh on sentiment, even though the scheduled nature of the trades reduces their signaling value. George Jenkins insider sale

About Palvella Therapeutics

Palvella Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for patients with rare and serious diseases. The company’s work centers on localized treatments intended to address conditions for which existing therapeutic options are limited.

Palvella’s lead investigational product is QTORIN 3.9%, a topical formulation of sirolimus designed to deliver the medicine directly to affected areas of the skin. The product is being developed for microcystic lymphatic malformations, rare vascular anomalies that can cause swelling, pain and disfigurement.